<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624778</url>
  </required_header>
  <id_info>
    <org_study_id>16233</org_study_id>
    <secondary_id>I5T-MC-AACD</secondary_id>
    <nct_id>NCT02624778</nct_id>
  </id_info>
  <brief_title>A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD</brief_title>
  <official_title>A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the
      safety of LY3002813 by looking at adverse events (side effects). The study will also look at
      the effect the body has on LY3002813. Study participants will have mild cognitive impairment
      (MCI) due to AD or mild to moderate AD.

      The study involves 3 parts.

        -  Part A in which participants will receive a single dose of LY3002813 or placebo (no
           drug).

        -  Part B in which participants will receive multiple doses of LY3002813 or placebo for 24
           weeks.

        -  Part C in which participants will receive multiple doses of LY3002813 or placebo for up
           to 72 weeks.

      Drug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C,
      the study will last approximately 72 weeks, not including screening of approximately 56 days.
      The study is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)</measure>
    <time_frame>Predose up to Day 505</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum Concentrations of LY3002813</measure>
    <time_frame>Predose up to Day 589</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Incidence of Anti-Drug Antibodies</measure>
    <time_frame>Predose up to Day 589</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>LY3002813 Single dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered intravenously (IV) once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Single dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Single dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Multiple dose 1 x 24 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV for 24 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Multiple dose 2 x 24 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Multiple dose 3 x 72 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV for 72 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813 Multiple dose 4 x 72 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3002813 administered IV for 72 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo given once</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo x 24 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV for 24 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo x 72 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV for 72 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3002813</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3002813 Single dose 1</arm_group_label>
    <arm_group_label>LY3002813 Single dose 2</arm_group_label>
    <arm_group_label>LY3002813 Single dose 3</arm_group_label>
    <arm_group_label>LY3002813 Multiple dose 1 x 24 wks</arm_group_label>
    <arm_group_label>LY3002813 Multiple dose 2 x 24 wks</arm_group_label>
    <arm_group_label>LY3002813 Multiple dose 3 x 72 wks</arm_group_label>
    <arm_group_label>LY3002813 Multiple dose 4 x 72 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo given once</arm_group_label>
    <arm_group_label>Placebo x 24 weeks</arm_group_label>
    <arm_group_label>Placebo x 72 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or
             mild-to-moderate AD

          -  Men or nonfertile women, at least 50 years of age. Nonfertile is defined as
             hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year

          -  Have up to 2 partners who will provide a separate written informed consent to
             participate

          -  Have adequate vision and hearing for neuropsychological testing in the opinion of the
             investigator

          -  Positive florbetapir scan

        Exclusion Criteria:

          -  Do not have up to 2 reliable partners who are in frequent contact with the
             participant, who will accompany the participant to the office and/or be available by
             telephone at designated times, and will monitor administration of prescribed
             medications

          -  Are being monitored for radiation due to occupational exposure to ionized radiation,
             or exposure to ionizing radiation within last 12 months from an investigational study

          -  History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous
             malformation, or carotid artery occlusion, or stroke or epilepsy

          -  Have any contraindications for magnetic resonance imaging (MRI) studies, including
             claustrophobia, the presence of contraindicated metal (ferromagnetic) implants,
             cardiac pacemaker

          -  Have allergies to humanized monoclonal antibodies, including proteins and
             diphenhydramine, epinephrine, and methylprednisolone

          -  Have gamma globulin therapy within the last year

          -  Previously dosed in any other study investigating active immunization against amyloid
             beta (Aβ)

          -  Previously dosed in any other study investigating passive immunization against Aβ
             within the last 6 months

          -  Have current serious or unstable illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Brody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-426-9299</phone>
    </contact>
    <investigator>
      <last_name>Craig Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-744-2025</phone>
    </contact>
    <investigator>
      <last_name>David Subich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-706-8760</phone>
    </contact>
    <investigator>
      <last_name>Paolo DePetrillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials, LC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-771-6387</phone>
    </contact>
    <investigator>
      <last_name>Daniel Gruener</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shawn Searle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN/studies/alzheimer's/aacd</url>
    <description>Click here for more information about this study: A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

